Phase 147 is the 147th phase created by CJ, shown in his 150 Phases, 163 Phases, and 200 phases template. Appearance. Original: Phase 147 looks like a creepy smiling mask with empty eye sockets. Gold XD Extension: A woman with many spider legs coming out of her eyes and mouth, almost reminiscent of Phoenix's 33 in a way. Origin

Phase 147.01 is the 1st subphase of Phase 147 in raysofdoom2665's 500 phase template. It looks like a human with a crow mask and an hoodie. The origin for this is SCP-049 Phase 126 with reversed and glitch noises.

2024年5月23日 · The Phase 1, first-in-human, open-label clinical study aims to evaluate the safety and preliminary efficacy of 225Ac-ABD-147 in patients with SCLC or LCNEC who previously received platinum-based therapy. The study will determine the recommended dose regimen for future development.

Phase 150 is the 150th phase of Mr. Incredible Becoming Canny and the final phase of Mr. Incredible Becoming Canny (150 Phases). It has a sub-phase. Phase 150 appears to be a planet but it's blue and a light of the sun is behind. The origin of this phase is Into The Helix-Verse. The audio for this phase is Bersek OST- Ghosts.

Mr. Incredible Becoming Uncanny/Canny (Phase Collection) MIBU 2000 Phases (NightmareKing) KunaProduction's Template; Nightmare King Grimm's Phases 1901-2000; ... Phase 147. Phase 148. Phase 149. Phase 150. Phase 150.5. Categories Categories: Stubs; Community content is available under CC-BY-SA unless otherwise noted.

Phase 47 is the forty-seventh phase in the history of Mr. Incredible Becoming Uncanny. Phase 47 looks like a blue spirit with its mouth open and glowing pupils. The origin is Anamoly name:Trollge...

2024年9月5日 · ABD-147 is a next-generation precision radiopharmaceutical biologic therapy designed to deliver Actinium-225 (225 Ac) to solid tumors expressing DLL3, a protein found on the surface of neuroendocrine tumors, but rarely expressed on the surface of normal cells or tissues.

2022年8月5日 · credit to @Juxyphlux for the beanos earrape

2024年9月6日 · ABD-147 is a next-generation precision radiopharmaceutical biologic therapy designed to deliver Actinium-225 (225Ac) to solid tumors expressing DLL3, a protein found on the surface of neuroendocrine tumors, but rarely expressed on the surface of normal cells or tissues.

A Phase 1a/b, Open-label, Dose-escalation Study of the Safety, Pharmacokinetics, and Initial Efficacy of 225Ac-ABD147 in Patients with Small Cell Lung Cancer and Large Cell Neuroendocrine Carcinoma of the Lung Following Platinum-based Chemotherapy